Method for treating and preventing disorders using optically pure (+) norcisapride

Abstract

Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.

1 - 27 . (canceled)  
     
     
         28 . A method of treating bradycardia or bradyarrhythmia in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.  
     
     
         29 . The method of  claim 28 , wherein the patient is a human.  
     
     
         30 . The method of  claim 28 , wherein (+) norcisapride is administered orally.  
     
     
         31 . The method of  claim 30 , wherein (+) norcisapride is administered as a tablet or a capsule.  
     
     
         32 . The method of  claim 28 , wherein the amount administered is from about 0.5 mg to about 500 mg.  
     
     
         33 . The method of  claim 32 , wherein the amount administered is from about 1 mg to about 250 mg.  
     
     
         34 . The method of  claim 28 , wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.  
     
     
         35 . The method of  claim 30 , wherein said (+) norcisapride is administered from one to four times per day.  
     
     
         36 . The method of  claim 28 , wherein (+) norcisapride is administered parenterally, transdermally, rectally, or sublingually.  
     
     
         37 . A method of treating asthma in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.  
     
     
         38 . The method of  claim 37 , wherein the patient is a human.  
     
     
         39 . The method of  claim 37 , wherein (+) norcisapride is administered orally.  
     
     
         40 . The method of  claim 39 , wherein (+) norcisapride is administered as a tablet or a capsule.  
     
     
         41 . The method of  claim 37 , wherein the amount administered is from about 0.5 mg to about 500 mg.  
     
     
         42 . The method of  claim 41 , wherein the amount administered is from about 1 mg to about 250 mg.  
     
     
         43 . The method of  claim 37 , wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.  
     
     
         44 . The method of  claim 39 , wherein said (+) norcisapride is administered from one to four times per day.  
     
     
         45 . The method of  claim 37 , wherein (+) norcisapride is administered parenterally, transdermally, rectally, or sublingually.  
     
     
         46 . A method of treating urinary incontinence in a patient which comprises administering to said patient in need of such treatment a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.  
     
     
         47 . The method of  claim 46 , wherein the patient is a mammal.  
     
     
         48 . The method of  claim 46 , wherein (+) norcisapride is administered orally.  
     
     
         49 . The method of  claim 48 , wherein (+) norcisapride is administered as a tablet or a capsule.  
     
     
         50 . The method of  claim 46 , wherein the amount administered is from about 0.5 mg to about 500 mg.  
     
     
         51 . The method of  claim 50 , wherein the amount administered is from about 1 mg to about 250 mg.  
     
     
         52 . The method of  claim 46 , wherein (+) norcisapride is administered together with a pharmaceutically acceptable carrier.  
     
     
         53 . The method of  claim 48 , wherein said (+) norcisapride is administered from one to four times per day.  
     
     
         54 . The method of  claim 46 , wherein (+) norcisapride is administered parenterally, transdermally, rectally, or sublingually.  
     
     
         55 - 67 . (canceled)  
     
     
         68 . A method of preventing or managing bradycardia or bradyarrhythmia in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) isomer.  
     
     
         69 . A method of preventing or managing asthma in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) isomer.  
     
     
         70 . A method of preventing or managing urinary incontinence in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) isomer.  
     
     
         71 . A method of preventing or managing apnea or apnea disorders in a patient which comprises administering to said patient in need of such prevention or management a therapeutically effective amount of (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) isomer.